Sugi Predict

Sugi Predict / Compounds / SCHEMBL2313435

SCHEMBL2313435

SCHEMBL2313435

c1ccc(C2(c3ccccc3)CCNC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 4/20 1.00
▸ OPRM1 P35372 6/20 0.75
▸ DRD2 P14416 1/20 0.55
▸ SLC6A2 P23975 1/20 0.55
▸ HTR2C P28335 1/20 0.55
▸ SLC6A4 P31645 1/20 0.55
▸ BACE1 P56817 1/20 0.50
▸ AKT2 P31751 1/20 0.47
▸ MEN1 O00255 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TACR1 P25103 1/20 0.40
▸ DRD4 P21917 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ GRIN2D O15399 1/20 0.38
▸ GRIN3B O60391 1/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ GRIN1 Q05586 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3695425 0.98 HTR2A (0.96) HTR2AOPRM1DRD2SLC6A2HTR2C
SCHEMBL2311486 0.87 HTR2A (0.77) HTR2AOPRM1DRD2SLC6A2HTR2C
SCHEMBL738518 0.86 OPRM1 (1.00) HTR2AOPRM1DRD2SLC6A2HTR2C
Hydrochloric Acid SCHEMBL1765279 0.85 HTR2A (0.74) HTR2AOPRM1DRD2SLC6A2HTR2C
Hydrochloric Acid SCHEMBL1765284 0.84 OPRM1 (0.95) HTR2AOPRM1DRD2SLC6A2HTR2C
SCHEMBL24481549 0.80 HTR2A (0.67) HTR2AOPRM1DRD2SLC6A2HTR2C
SCHEMBL3032516 0.78 HTR2A (0.64) HTR2AOPRM1DRD2SLC6A2HTR2C
SCHEMBL2313549 0.78 HTR2A (0.64) HTR2AOPRM1DRD2SLC6A2HTR2C
SCHEMBL7885473 0.78 OPRM1 (0.83) HTR2AOPRM1DRD2SLC6A2HTR2C
Acetic Acid SCHEMBL8333150 0.75 OPRM1 (0.77) HTR2AOPRM1AKT2MEN1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116546990-B CD73 inhibitor and pharmaceutical application thereof RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) 2026-05-26 — — CN disclosed
CN-114539340-B CD73 inhibitor and pharmaceutical application thereof 润佳（苏州）医药科技有限公司 2024-06-07 — — CN disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2024-01-25 — — US disclosed
EP-4251633-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-10-04 — — EP disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-09-21 — — US disclosed
CN-116546990-A CD73 inhibitor and pharmaceutical application thereof 润佳（苏州）医药科技有限公司 2023-08-04 — — CN disclosed
EP-1670470-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2006-06-21 — — EP disclosed
WO-2005030209-A1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2005-04-07 — — WO disclosed
US-6172073-B1 BENZIMIDAZOLYLOXY ALKANAMINES AS SEROTONIN REUPTAKE INHIBITORS; NICOTINE AND TOBACCO WITHDRAWAL; PSYCHOLOGICAL, EATING, BRAIN, GASTROINTESTINAL, SLEEP, AND SEXUAL DISORDERS ELI LILLY AND COMPANY 2001-01-09 — — US disclosed
US-5789402-A Compounds having effects on serotonin-related systems ELI LILLY COMPANY (US) 1998-08-04 — — US disclosed
US-5741789-A HETERO-OXY ALKANAMINES ELI LILLY AND COMPANY (US) 1998-04-21 — — US disclosed
US-5627196-A ANTIDEPRESSANTS AND ANTISEROTONIN AGENTS ELI LILLY AND COMPANY (US) 1997-05-06 — — US disclosed
US-5614523-A INDOLYLOXY COMPOUNDS ELI LILLY AND COMPANY (US) 1997-03-25 — — US disclosed
US-5576321-A ALKOXY-SUBSTITUTED INDOLES ELI LILLY AND COMPANY (US) 1996-11-19 — — US disclosed
WO-1996022290-A1 COMPOUNDS HAVING EFFECTS ON SEROTONIN-RELATED SYSTEMS ELI LILLY AND COMPANY (US) 1996-07-25 — — WO disclosed
EP-0722941-A2 Compounds having effects on serotonin-related systems ELI LILLY AND COMPANY (US) 1996-07-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295213-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 HTR2A 2065/4885OPRM1 3364/4885DRD2 3813/4885
US-20240024346-A1 CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF ENTPD5, NT5E, ENTPD1 HTR2A 2065/4885OPRM1 3364/4885DRD2 3813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.